USPTO Art Unit 1642 Prosecution Statistics

Art Unit Information

Art Unit: 1642
Group: 1640
Tech Center: 1600
Total Cases: 11,902
Last Active: August 2025

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19304112ANTI-TRANSFERRIN RECEPTOR FUSION PROTEINS AND METHODS OF USE THEREOFAugust 2025March 2026Allow710YesNo
19227795PHARMACEUTICAL COMBINATIONSJune 2025February 2026Allow910YesNo
19218154ANTI-HUMAN C5 ANTIBODIESMay 2025October 2025Allow520YesNo
19190098COMBINATION OF LURBINECTEDIN AND IMMUNE CHECKPOINT INHIBITORSApril 2025December 2025Allow810YesNo
19059303METHOD FOR IDENTIFYING A SHARED NEOANTIGEN-REACTIVE T CELL RECEPTORFebruary 2025August 2025Allow610NoNo
18727602BIOMARKER FOR PREDICTING THE PROGNOSIS OF COLORECTAL CANCERFebruary 2025December 2025Allow1711NoNo
19025781RNASE-PON1 FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODSJanuary 2025October 2025Allow911NoNo
18991315Subcutaneous anti-HER2 Antibody Formulations and Uses ThereofDecember 2024March 2025Allow310NoNo
18923463POLYNUCLEOTIDES ENCODING PARAOXONASE FUSION POLYPEPTIDESOctober 2024December 2024Allow100NoNo
18898854Antibodies Targeting ActRIIA and ActRIIBSeptember 2024December 2024Abandon300NoNo
18890453ACTIVATION OF BIOLUMINESCENCE BY STRUCTURAL COMPLEMENTATIONSeptember 2024March 2025Allow610YesNo
18810362HETERODIMERIC ANTIBODIES THAT BIND CD3 AND CLDN6August 2024May 2025Allow820NoNo
18765553CANCER VACCINES TARGETING SURVIVIN AND USES THEREOFJuly 2024March 2026Allow2011NoNo
18726319ANTI-VARIABLE MUC1* ANTIBODIES AND USES THEREOFJuly 2024August 2025Allow1301YesNo
18758038Trispecific T cell EngagersJune 2024December 2025Allow1721YesNo
18759723ANTIBODY-DRUG CONJUGATES AND USES THEREOFJune 2024December 2024Allow610YesNo
18749771COMPOSITIONS AND METHODS FOR DETECTING PANCREATIC CANCERJune 2024June 2025Allow1211YesNo
18749504DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITYJune 2024January 2025Allow710YesNo
18749522DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITYJune 2024March 2025Allow910YesNo
18738887Cancer TreatmentsJune 2024November 2025Abandon1811NoNo
18737881METHODS OF TREATING GLIOBLASTOMASJune 2024December 2025Allow1820NoNo
18674612DOSAGE OF CLAUDIN-6 CONJUGATES FOR CANCER TREATMENTMay 2024April 2025Allow1120YesNo
18652576ANTI-AMYLOID BETA PROTOFIBRIL/OLIGOMER ANTIBODIES AND USES THEREOFMay 2024January 2026Abandon2001NoNo
18644619SYSTEM AND SENSOR ARRAYApril 2024February 2025Allow1012NoNo
18635280Subcutaneous anti-HER2 Antibody Formulations and Uses ThereofApril 2024January 2026Abandon2110NoNo
18628200RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERSApril 2024February 2025Allow1110NoNo
18628224USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH ANTI-CD27 ANTIBODY IN CANCER TREATMENTApril 2024December 2025Abandon2020NoNo
18624620BIOMARKERS FOR PANCREATIC CANCERApril 2024February 2026Allow2310NoNo
18622066Engineered Expression of Cell Surface and Secreted Sialidase by CAR T Cells for Increased Efficacy in Solid TumorsMarch 2024October 2025Allow1911YesNo
18619805ANTI-OX40 ANTAGONISTIC ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASESMarch 2024October 2025Abandon1910NoNo
18691316ANTI-PERIOSTIN HUMANIZED MONOCLONAL ANTIBODY, AND PREPARATION METHOD THEREFOR AND USE THEREOFMarch 2024March 2026Allow2400YesNo
18600481BISPECIFIC ANTIGEN BINDING MOLECULES THAT BIND HER2, AND METHODS OF USE THEREOFMarch 2024December 2025Allow2111NoNo
18593028ATP-Dependent Agonists of Immune Cells Function as Anticancer AgentsMarch 2024August 2024Allow500NoNo
18592208METHODS OF TREATING TUMORFebruary 2024March 2025Allow1210NoNo
18429111[3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOL-5-YL]METHANOL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDJanuary 2024June 2025Abandon1621NoNo
18427038ANTI-DCLK1 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS OF USE THEREOFJanuary 2024June 2025Allow1601NoNo
18426324PE-STOP Gene Editing System and Gene Knockout Method and ApplicationJanuary 2024April 2025Abandon1521YesNo
18417162PROSTATE ANTIGEN STANDARDS AND USES THEREOFJanuary 2024August 2025Allow1921NoNo
18417299ANTI-AMYLOID BETA PROTOFIBRIL/OLIGOMER ANTIBODIES AND USES THEREOFJanuary 2024June 2024Allow511YesNo
18412245COMPOSITIONS AND METHODS COMPRISING SFRP2 ANTAGONISTSJanuary 2024November 2024Allow1000NoNo
18408377METHODS OF USING ANTI-SP17 IMMUNOTHERAPEUTICSJanuary 2024November 2024Allow1010YesNo
18405910BINDING MOLECULESJanuary 2024June 2024Allow601YesNo
18396461ANTI-TSPAN8/ANTI-CD3 BISPECIFIC ANTIBODY AND ANTI-TSPAN8 ANTIBODYDecember 2023January 2025Allow1310NoNo
18393153METHODS FOR MODULATING AN IMMUNE RESPONSEDecember 2023December 2024Abandon1211NoNo
18545890CLAUDIN 4 AND CLAUDIN 9 ANTIBODIES AND METHODS OF TREATING CANCERDecember 2023September 2025Abandon2110NoNo
18542441T CELL RECEPTORS AND FUSION PROTEINS THEREOFDecember 2023April 2024Allow400NoNo
18541600COMBINATION THERAPIES FOR TREATING CANCERDecember 2023March 2025Abandon1510NoNo
18537973COMPOSITION OF BL-8040December 2023October 2024Allow1020YesNo
18538242ANTIGEN BINDING PROTEINS SPECIFICALLY BINDING MAGE-ADecember 2023December 2024Allow1221YesNo
18537241Predicting Prognosis and Treatment Response of Breast Cancer Patients Using Expression and Cellular Localization of N-MyristoyltransferaseDecember 2023January 2026Allow2510NoNo
18532450SYSTEMS AND METHODS FOR BARRETT'S ESOPHAGUS PATHOGENESIS AND ESOPHAGEAL ADENOCARCINOMA PROGRESSION REVEALING MARKERSDecember 2023March 2025Allow1621NoNo
18531287DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIESDecember 2023August 2024Abandon800NoNo
18529758COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTSDecember 2023February 2025Allow1420NoNo
18529140COMBINATION CANCER THERAPYDecember 2023December 2025Abandon2420YesYes
18529537MYCOVIRUS-INDUCED GENE SILENCING VECTOR, CONSTRUCTION METHOD AND APPLICATION THEREOFDecember 2023August 2024Allow810NoNo
185246133E8.scFv.Cys-IR800 Conjugate Targeting TAG-72 in an Orthotopic colorectal cancer modelNovember 2023March 2025Allow1610NoNo
18523859IMMUNOASSAY-BASED DETERMINATION OF IN-SOLUTION BINDING KINETICSNovember 2023May 2025Allow1810NoNo
18516168RESPONSE TO EGFR BLOCKADENovember 2023April 2025Abandon1710NoNo
18512556FC FUSION MOLECULES AND USES THEREOFNovember 2023June 2024Allow701YesNo
18509504Conjugate MoleculesNovember 2023June 2024Allow720NoNo
18507167ANTIBODIES, ACTIVATABLE ANTIBODIES, BISPECIFIC ANTIBODIES, AND BISPECIFIC ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOFNovember 2023July 2025Allow2021NoNo
18501589Tetravalent FZD and WNT Co-receptor Binding Antibody Molecules and Uses ThereofNovember 2023January 2025Abandon1511YesNo
18500831COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODYNovember 2023November 2025Abandon2410NoNo
183864215-((2-ISOPROPYL-5-METHYLPHENOXY)METHYL)-3-(NAPHTHALEN-2-YL)-1,2,4-OXADIAZOLE AS AN ANTI-CANCER AND ANTIMICROBIAL COMPOUNDNovember 2023February 2024Allow310YesNo
18498843ENGINEERED SIRPa VARIANTS AND METHODS OF USE THEREOFOctober 2023December 2024Allow1341YesNo
18495585CIRCULATING TUMOR CELL DIAGNOSTICS FOR BIOMARKERS PREDICTIVE OF RESISTANCE TO ANDROGEN RECEPTOR (AR) TARGETED THERAPIESOctober 2023September 2025Abandon2210NoYes
18493604BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENTOctober 2023August 2025Abandon2210NoNo
18381344INTRACELLULAR DELIVERY COMPOSITIONSOctober 2023April 2025Allow1821YesNo
18487818METHODS AND COMPOSITIONS FOR DIAGNOSING AND TREATING PROSTATE CANCER BASED ON LONG NONCODING RNA OVERLAPPING THE LCK GENE THAT REGULATES PROSTATE CANCER CELL GROWTHOctober 2023April 2025Abandon1810NoNo
18286471ANTI-C1s ANTIBODYOctober 2023March 2026Allow2900YesNo
18482643Targeting Intracellular Target-Binding Determinants with Intracellular AntibodiesOctober 2023June 2024Allow811NoNo
18481291METHODS OF TREATING HER2-POSITIVE CANCEROctober 2023June 2024Abandon800NoNo
18477722COMBINATION THERAPY WITH AN ANTI-HER2 ANTIBODY-DRUG CONJUGATE AND A BCL-2 INHIBITORSeptember 2023June 2024Abandon800NoNo
18478808CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSIONSeptember 2023February 2026Allow2800NoNo
18475552Anti-TIM-3 Antibodies and Use ThereofSeptember 2023February 2025Abandon1710NoNo
18372933DEVICE AND METHOD FOR DETECTION OF ANALYTESSeptember 2023December 2024Allow1510NoNo
18473026THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITECAN (IMMU-132)September 2023March 2026Abandon3010NoNo
18471388HUMANIZED ANTI-IL-1R3 ANTIBODY AND METHODS OF USESeptember 2023March 2024Allow610YesNo
18471193ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURESeptember 2023May 2024Abandon800NoNo
18469913METHODS AND SYSTEMS FOR SELECTIVE QUANTITATION AND DETECTION OF ALLERGENS INCLUDING GLY M 7September 2023January 2026Abandon2710NoNo
18368138[3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOL-5-YL]METHANOL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUNDSeptember 2023October 2024Abandon1311NoNo
18464469METHODS OF USING TUMOR INFILTRATING LYMPHOCYTES IN DOUBLE-REFRACTORY MELANOMASeptember 2023February 2026Allow2910YesNo
18244135BISPECIFIC ANTIBODY MOLECULES BINDING TO CD3 AND EGFRvIIISeptember 2023July 2025Allow2240YesNo
18463209HETERODIMERIC PROTEINSSeptember 2023May 2025Allow2010NoNo
18462648OVARIAN CANCER VACCINESSeptember 2023March 2025Allow1820NoNo
18459857Subcutaneous anti-HER2 Antibody Formulations and Uses ThereofSeptember 2023June 2024Abandon1010NoNo
18460254METHODS AND DEVICES FOR ASSAYING A BIOLOGICAL SAMPLESeptember 2023July 2024Allow1041YesNo
18460221SYSTEM AND SENSOR ARRAYSeptember 2023March 2024Allow610YesNo
18459842METHODS FOR TREATING CANCER WITH ANTI-PD-1 ANTIBODIESSeptember 2023February 2025Abandon1800NoNo
18239348NOVEL POTASSIUM CHANNEL INHIBITORSAugust 2023November 2023Allow310NoNo
18456503ANTIBODY THAT SPECIFICALLY BINDS TO HUMAN CTLA4 AND MEDICAMENTS AND KITS COMPRISING THE SAMEAugust 2023March 2026Allow3000YesNo
18456044NOVEL THI-INDUCING ADJUVANT COMPRISING COMBINATION OF DIFFERENT NUCLEIC ACID ADJUVANTS AND USE OF SAMEAugust 2023May 2025Allow2130NoNo
18456262ANTI-SEZ6 ANTIBODY DRUG CONJUGATESAugust 2023July 2024Allow1020NoNo
18455176IMMUNE-STIMULATING IL-2 FUSION PROTEINSAugust 2023October 2025Abandon2501NoNo
18452972METHODS OF TREATING CANCERAugust 2023May 2025Abandon2111NoNo
18451990TREATMENT OF LAG-3 POSITIVE TUMORSAugust 2023March 2024Allow700NoNo
18546413PARAOXONASE FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODSAugust 2023July 2024Allow1211NoNo
18263430ANTI-NECTIN-4-ANTIBODIES AND USES THEREOFJuly 2023March 2024Allow810NoNo
18227057METHODS FOR MODULATING AN IMMUNE RESPONSEJuly 2023January 2024Allow621NoNo
18357013CONSTRAINED CONDITIONALLY ACTIVATED BINDING PROTEINSJuly 2023June 2024Allow1111YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for art-unit 1642.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
144
Examiner Affirmed
98
(68.1%)
Examiner Reversed
46
(31.9%)
Reversal Percentile
48.0%
Lower than average

What This Means

With a 31.9% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
1244
Allowed After Appeal Filing
228
(18.3%)
Not Allowed After Appeal Filing
1016
(81.7%)
Filing Benefit Percentile
4.0%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 18.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Art Unit 1642 - Prosecution Statistics Summary

Executive Summary

Art Unit 1642 is part of Group 1640 in Technology Center 1600. This art unit has examined 11,902 patent applications in our dataset, with an overall allowance rate of 48.9%. Applications typically reach final disposition in approximately 35 months.

Comparative Analysis

Art Unit 1642's allowance rate of 48.9% places it in the 7% percentile among all USPTO art units. This art unit has a significantly lower allowance rate than most art units at the USPTO.

Prosecution Patterns

Applications in Art Unit 1642 receive an average of 2.00 office actions before reaching final disposition (in the 59% percentile). The median prosecution time is 35 months (in the 29% percentile).

Strategic Considerations

When prosecuting applications in this art unit, consider the following:

  • The art unit's allowance rate suggests a more challenging examination environment compared to the USPTO average.
  • With more office actions than average, plan for relatively streamlined prosecution.
  • The median prosecution time is longer than average and should be factored into your continuation and client communication strategies.
  • Review individual examiner statistics within this art unit to identify examiners with particularly favorable or challenging prosecution patterns.

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.